Plural Ring Nitrogens In The Tricyclo Ring System Patents (Class 514/292)
  • Patent number: 10947236
    Abstract: In one aspect, the invention provides compounds of Formula I Formula Ia, Formula Ib, Formula Ic, and Formula Id and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes bone loss, and cancer, using a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: March 16, 2021
    Assignee: OsteoQC Inc.
    Inventors: Debra Ellies, F. Scott Kimball, Robert N. Young
  • Patent number: 10766898
    Abstract: The invention provides compounds of Formula XXIII: wherein R1 is hydrogen, alkyl, acyl, or silyl, R2 is hydrogen, alkyl, benzyl, acyl, or ester, and R3 is hydrogen, alkyl, an aromatic group, azacyclic, carbocycle, aryl, cycloalkyl, heterocycloalkyl, heterocycle, heteroaryl, heteroalkyl, acyl, or ester, as well as derivatives and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: September 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
  • Patent number: 10744122
    Abstract: The invention relates to an adhesive transdermal therapeutic system containing, as an active principle, an association of valentonin (VLT) and 6-methoxyharmalan (6-MH).
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: August 18, 2020
    Inventors: Jean-Bernard Fourtillan, Marianne Fourtillan
  • Patent number: 10736888
    Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: August 11, 2020
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Anthony Coates, Yanmin Hu
  • Patent number: 10709798
    Abstract: A composition comprising a tricyclic indole compound. The composition has a higher purity and better impurity profile than known compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use in vivo as a therapeutic or diagnostic agent.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: July 14, 2020
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Sondre Nilsen, Srinath Balaji Aralikatti Prahladachar Balaji, Umamaheshwar P. Mokkapati, Afsal Mohammed Kadavilpparampu Mohamed
  • Patent number: 10702488
    Abstract: The invention relates to a composition for induction of activity of a nuclear receptor PPAR? and inhibition of HDAC in a subject in need thereof, which comprises a synergistic combination of benzoate and phenylbutyrate and/or phenylacetate in association with a pharmaceutical carrier.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: July 7, 2020
    Assignee: Theriac Biomedical Inc.
    Inventor: Tony Antakly
  • Patent number: 10702519
    Abstract: The present invention relates to use of pyrroloquinoline quinone (PQQ), a derivative and/or a salt thereof of formula (I) in the preparation of a drug for treating and/or preventing primary Sjogren's syndrome, secondary Sjogren's syndrome as well as dry mouth, dry eye and multiple system damages accompanied by the involvement of other exocrine glands and other organs outside the glands caused by Sjogren's syndrome. In formula (I), R1, R2 and R3 being same or different, each independently representing lower alkyl, lower alkenyl, lower alkynyl, aralkyl, alkaryl, phenyl, a hydrogen atom, sodium atom or a potassium atom; and PQQ or pharmaceutical combinations of PQQ combined with active vitamin D, NAC, resveratrol, epigallocatechin gallate, curcumin, anthocyanin, vitamin E, vitamin C, or vitamin D and the like. The drug and the pharmaceutical combinations can treat Sjogren's syndrome and associated diseases which are derivative of Sjogren's syndrome.
    Type: Grant
    Filed: January 22, 2017
    Date of Patent: July 7, 2020
    Assignee: NANJING SHUPENG LIFESCIENCE CO., LTD
    Inventors: Chuanjun Wen, Fenyong Sun
  • Patent number: 10653679
    Abstract: The present disclosure provides, among other things, compositions and methods useful for inhibiting bacteria, such as Mycobacterium tuberculosis. These compositions and methods find many uses in medicine and research, e.g., treating subjects afflicted with active or latent bacterial infections. The compositions described herein are also useful for decontaminating surfaces (e.g., surgical tools or implants).
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: May 19, 2020
    Assignee: Board of Trustees of Michigan State University
    Inventors: Robert Abramovitch, Benjamin K. Johnson, Christopher J. Colvin
  • Patent number: 10590132
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: March 17, 2020
    Assignee: AstraZeneca AB
    Inventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
  • Patent number: 10544138
    Abstract: Provided herein are tricyclic small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK). The compounds are useful for treating cancer and other conditions or diseases associated with aberrant MELK expression. Also provided herein are pharmaceutical compositions comprising a tricyclic compound of the invention and a pharmaceutically acceptable carrier. The invention also provides methods of treating cancers associated with over-expression of MELK.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 28, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Tinghu Zhang, Hai-Tsang Huang, Yubao Wang, Jean Zhao, Hwan Geun Choi
  • Patent number: 10493127
    Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: December 3, 2019
    Assignee: Arch Biopartners, Inc.
    Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing Sze Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
  • Patent number: 10472355
    Abstract: An SP-141 compound is a novel small molecule that can serve as a molecular-targeted chemotherapeutic agent. In one embodiment, the labeled compound can comprise SP-141, which comprises 6-methoxy-1-(naphthalen-1-yl)-9 H-pyrido[3,4-b]indote. The compound inhibits expression of oncogenes such as the Mouse Double Minute 2 protein. The compound can bind directly to Mouse Double Minute 2 to inhibit cancer growth including breast cancer growth.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: November 12, 2019
    Assignee: Texas Tech University System
    Inventors: Ruiwen Zhang, Wei Wang
  • Patent number: 10364244
    Abstract: Provided are crystal forms I, II, III and IV of a pyrroloquinoline quinone sodium salt and a preparation method thereof. Also provided are a pharmaceutical composition, a cosmetic composition, a functional food or a nutritional agent containing the above-mentioned crystal forms. The crystal forms have excellent properties in terms of solubility, crystal stability, hygroscopicity and the like.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 30, 2019
    Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Zhiqing Yang, Liang Zhang, Xiangyang Zhang, Zhenjuan Shi, Min Zhao, Hongying Luo
  • Patent number: 10351565
    Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: July 16, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
  • Patent number: 10351566
    Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: July 16, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
  • Patent number: 10344030
    Abstract: The present application provides a hetero-cyclic compound which may significantly improve the service life, efficiency, electrochemical stability, and thermal stability of an organic light emitting device, and an organic light emitting device in which the hetero-cyclic compound is contained in an organic compound layer.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 9, 2019
    Assignee: HEESUNG MATERIAL LTD.
    Inventors: Jung-Hyun Lee, Kee-Yong Kim, Yong-Hoon An, Jin-Seok Choi, Dae-Hyuk Choi, Sung-Jin Eum, Joo-Dong Lee
  • Patent number: 10307407
    Abstract: The present disclosure provides substituted 9H-pyrimido [4,5-b] indoles and 5H-pyrido [4,3-b] indoles and related analogs represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, W, B1, B2, G, X1, Y1, Y2, and Y3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer. The present disclosure is also directed to the use of compound of Formula I as synthetic intermediates.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: June 4, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yujun Zhao, Bing Zhou, Angelo Aguilar
  • Patent number: 10221173
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: March 5, 2019
    Assignee: AstraZeneca AB
    Inventors: Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
  • Patent number: 10155762
    Abstract: The invention provides compounds of Formula XXIII: wherein R1 is hydrogen, alkyl, acyl, or silyl, R2 is hydrogen, alkyl, benzyl, acyl, or ester, and R3 is hydrogen, alkyl, an aromatic group, azacyclic, carbocycle, aryl, cycloalkyl, heterocycloalkyl, heterocycle, heteroaryl, heteroalkyl, acyl, or ester, as well as derivatives and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: December 18, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
  • Patent number: 10130617
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 to R5 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: November 20, 2018
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, David Buttar, Christopher De Savi, Craig Samuel Donald, Richard Albert Norman, Alfred Arthur Rabow, Gordon Stuart Currie, Heather Redfearn, Nadim Akhtar, Helen Elizabeth Williams, Matthew Osborne, Neda Yavari
  • Patent number: 10117867
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: November 6, 2018
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence P. Wennogle
  • Patent number: 10047089
    Abstract: In one embodiment, the present application discloses 2-aza-, 2-oxa- and 2-thia-2,3-dihydro-6-azaphenalene compounds and compositions, and methods for treating a neurological disease in a patient in need thereof using the compounds and compositions as disclosed herein.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: August 14, 2018
    Assignee: Collaborative Medicinal Development, LLC
    Inventors: John C. Warner, Jeffery Allen Gladding, Srinivasa R. Cheruku, Dieu Nguyen, Jean R. Loebelenz, James J. Norman, Sambaiah Thota, John W. Lee, Craig Rosenfeld
  • Patent number: 10040795
    Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: August 7, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
  • Patent number: 10040791
    Abstract: It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R1, R2, R3, Y, and Z are as defined in claim 1.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: August 7, 2018
    Assignees: Daiichi Sankyo Company, Limited, National Cancer Center
    Inventors: Shoichi Saito, Masao Itoh, Tetsunori Fujisawa, Hironao Saito, Yohei Kiyotsuka, Hideaki Watanabe, Hironori Matsunaga, Yoshiko Kagoshima, Tetsuya Suzuki, Yoko Ogawara, Kazuo Kitabayashi
  • Patent number: 10000483
    Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and/or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: June 19, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Nathanael Gray, Steven Balk, Qingsong Liu, Sen Chen
  • Patent number: 10000785
    Abstract: A composition of redox-reagent containing metal-containing complex and thionine or its derivative as electron transfer mediator for use in an electrochemical biosensor, and a biosensor containing the same are provided. With the increase in reaction rate between redox enzyme-thionine (or its derivative)-metal-containing complex in the composition of redox-reagent containing metal-containing complex and thionine or its derivative, glucose detection efficiency markedly increases, and the composition is hardly influenced from high humidity and interfering substances. Accordingly, the composition of redox-reagent is useful in fabricating an electrochemical biosensor for detecting glucose in blood.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: June 19, 2018
    Assignee: I-SENS, INC.
    Inventors: Sung-kwon Jung, Moon Hwan Kim, Myeong-Ho Lee, Ung-Ki Lee, Yeon-Ho Jung, Han-Be Park, Hakhyun Nam, Geun Sig Cha
  • Patent number: 9994572
    Abstract: The invention provides compounds of Formula 1: and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 12, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Jacob Cornelis Russcher, Menno Cornelis Franciscus Monnee
  • Patent number: 9950062
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: April 24, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Manmohan Singh, David Skibinski, Simona Cianetti, Francesco Doro, Siddhartha Jain
  • Patent number: 9879003
    Abstract: Novel antiviral compounds of Formulae (I)-(III) are provided: (I) (II) (III) The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 30, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Nathanael Gray, Priscilla Yang, Qingsong Liu, Mélissanne de Wispelaere
  • Patent number: 9821031
    Abstract: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-I) receptor, e.g. a GLP-I fragment or analogue thereof.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: November 21, 2017
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Doris Stoffers, Diva D. De Leon, Charles Stanley
  • Patent number: 9732079
    Abstract: A yellow reduced pyrroloquinoline quinone crystal having a solubility in water of 0.040 to 0.20 (mg/mL).
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: August 15, 2017
    Assignee: Mitsubishi Gas Chemical Company, Inc.
    Inventor: Kazuto Ikemoto
  • Patent number: 9725444
    Abstract: Compounds as inhibitors of CSCPK and related kinases. The compounds are thiazole-substituted indolin-2-ones and are prepared from indolin-2-ones. They are included in pharmaceutical compositions and both the compounds and the pharmaceutical compositions are used in inhibiting cancer stem cells and in the treatment of a protean kinase related disorders.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: August 8, 2017
    Assignee: BOSTON BIOMEDICAL, INC
    Inventors: Chiang Jia Li, Ji-Feng Liu, Youzhi Li, Wei Li, Harry Rogoff
  • Patent number: 9669018
    Abstract: Disclosed are methods of preparing a pharmaceutical composition that is a mucoadhesive film by: (i) combining a film-forming mucoadhesive polymer, apomorphine particles containing an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form an intermediate film including the apomorphine particles; where the method further includes contacting or impregnating the intermediate film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: June 6, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Patent number: 9669020
    Abstract: The invention features mucoadhesive sublingual films containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine. The pH neutralizing agent in these films can be sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, potassium phosphate monobasic, potassium phosphate dibasic, potassium phosphate tribasic, or a mixture thereof.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: June 6, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Patent number: 9669019
    Abstract: Disclosed are sublingual formulations of apomorphine in unit dosage form formulated for sublingual administration, where the unit dosage form is a mucoadhesive film containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine, and where the mucoadhesive film is formed by the steps of: (i) combining a film-forming mucoadhesive polymer, apomorphine particles comprising an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form a first film comprising the apomorphine particles, where the steps further include contacting or impregnating the first film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: June 6, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Patent number: 9669021
    Abstract: Disclosed are methods of treating Parkinson's disease by (i) providing a pharmaceutical composition in unit dosage form that is a film having a first portion including apomorphine particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent, where the film contains the acid addition salt of apomorphine in an amount effective to treat Parkinson's disease, and (ii) administering the film by placing the film sublingually in the mouth of the subject and contacting sublingual mucosal tissue with the film.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 6, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Patent number: 9655886
    Abstract: The present invention relates to a method of antagonizing a 5-HT6 serotonin receptor, comprising administering to the cell a compound of formula 1.2, or a pharmaceutically acceptable salt thereof, wherein: R1 is a C1-C5 alkyl; R2i is independently hydrogen, halogen, a C1-C3 alkyl, CF3, OCF3 or OCH3; i is 1, 2, 3 or 4; Ar is an unsubstituted phenyl or a substituted phenyl substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle with one or two nitrogen atoms in the heterocycle. The invention also relates to pharmaceutical compositions and method for treating a cognitive disorder or neurodegenerative disease in a subject in need thereof comprising administering an effective dose to the subject of a compound of formula 1.2 according to claim 1, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: May 23, 2017
    Inventors: Alexandre Vasilievich Ivachtchenko, Andrey Alexandrovich Ivashchenko, Nikolay Filippovich Savchuk
  • Patent number: 9572817
    Abstract: The present invention relates to the field of therapy and prophylaxis of vascular tissue damage and/or complications and/or disease of vascular tissue by vascular regeneration and endothelium repair. The inventors have found that administration of an androgen receptor agonist alleviates one or more adverse vascular diseases and/or vascular complications thereof or adverse effects of androgen deficiency, with implications for prophylactic and therapeutic interventions.
    Type: Grant
    Filed: July 4, 2008
    Date of Patent: February 21, 2017
    Assignee: THE HEART RESEARCH INSTITUTE LTD.
    Inventors: Daniel Peter Sieveking, Martin Kean Chong Ng
  • Patent number: 9527854
    Abstract: Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor ?2B antagonists. The compounds may also bind to and antagonize adrenergic receptor ?1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: December 27, 2016
    Assignee: Medivation Technologies, Inc.
    Inventors: Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain, Michael John Green
  • Patent number: 9526776
    Abstract: Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: December 27, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Barbara Baudner, Derek O'Hagan, Manmohan Singh, Simone Bufali
  • Patent number: 9517263
    Abstract: The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) polymeric particles and (c) a benzonaphthyridine compound, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides, inter alia, methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: December 13, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Sushma Kommareddy
  • Patent number: 9394298
    Abstract: An object of the present invention is to provide a pyrroloquinoline quinone tetraalkali salt needing no special reagent, having a high solubility in a solvent, being capable of providing a high-concentration pyrroloquinoline quinone aqueous solution, being hardly changed in color even if being concurrently used with ascorbic acid, and being of a high quality and a high purity; a crystal of a pyrroloquinoline quinone tetrasodium salt; a composition; and a simple method for producing the pyrroloquinoline quinone tetraalkali salt. The pyrroloquinoline quinone tetraalkali salt is represented by the formula (1): wherein M is each independently one selected from the group consisting of Li, K, Na, Rb and Cs.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: July 19, 2016
    Assignee: Mitsubishi Gas Chemical Company, Inc.
    Inventor: Kazuto Ikemoto
  • Patent number: 9394296
    Abstract: The present invention features tryptoline derivatives and related compounds having kinase inhibitory activity. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions, such as cancers, inflammatory disorders, or autoimmune disorders.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: July 19, 2016
    Assignee: X-Chem, Inc.
    Inventors: Anthony D. Keefe, Richard W. Wagner, Matthew Clark, Ying Zhang, Diana Gikunju, John Cuozzo, Heather Thomson
  • Patent number: 9359379
    Abstract: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: June 7, 2016
    Assignee: InterMune, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Johnnie Y. Ramphal, Kumaraswamy Emayan, Scott D. Seiwert
  • Patent number: 9326981
    Abstract: The invention features methods involving the use of sublingual film formulations of apomorphine for treating Parkinson's disease. The methods involve providing the sublingual film formulation and administering the sublingual film formulation sublingually in the mouth of a subject by contacting sublingual mucosal tissue with the film.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 3, 2016
    Assignee: Cynapsus Therapeutics, Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Patent number: 9314468
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: April 19, 2016
    Assignee: Altiris Therapeutics, Inc.
    Inventors: Michael P Clark, Florence F Wagner, Michael G Natchus, Brandon C Doroh, Tricia L Johnson, Yesim Altas Tahirovic, Lawrence Wilson, John M Wiseman, Jason W Skudlarek, Mark A Lockwood
  • Patent number: 9283240
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: March 15, 2016
    Assignee: ABBOTT LABORATORIES
    Inventors: Rachael Buck, Geralyn O. Duska-McEwen, Joseph P. Schaller
  • Patent number: 9255094
    Abstract: Provided are new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Also provided are pyrido[4,3-b]indoles, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: February 9, 2016
    Assignee: Medivation Technologies, Inc.
    Inventors: Rajendra Parasmal Jain, Sarvajit Chakravarty
  • Patent number: 9221817
    Abstract: The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [?]D=?38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: December 29, 2015
    Assignee: SANOFI
    Inventors: Jean-Christophe Carry, Michel Cheve, Francois Clerc, Cecile Combeau, Sylvie Gontier, Alain Krick, Sylvette Lachaud, Laurent Schio
  • Patent number: 9216186
    Abstract: This invention relates to the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof in combination with an aminoglycoside antimicrobial agent for the prevention and/or treatment of microbial infections.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: December 22, 2015
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Yanmin Hu, Anthony R. M. Coates